Manufacturing Contracts

Nordion offers tailored solutions, leading expertise, and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development.

Our past and present commercial partnerships have been integral to our success to date and are key to our future growth.

Current Partners

 Partner Partner's Product Medical Isotope Services and Expertise  

TheraSphere®

TheraSphere® is a targeted liver cancer therapy that consists of millions of small glass microspheres (20 to 30 micrometers in diameter, or about a third of the width of a human hair).

Yttrium-90
  • Clinical supply
  • Commercial supply
  • Manufacture
  • Scale-up

NAV5001

The NAV5001 molecular imaging agent is being developed to aid in the diagnosis of Parkinson's Disease.

Iodine-123
  • Process development
  • Scale-up
  • Clinical supply

Previous Partners

 Partner Partner's Product Medical Isotope Services and Expertise  
Alseres   Pharmaceuticals Altropane®
The Altropane molecular imaging agent is being developed to aid in the diagnosis of Parkinson's Disease.
Iodine-123
  • Process development
  • Scale-up
  • Clinical supply
Imaging services based on Annexin, an imaging agent that binds to cells undergoing apoptosis. Iodine-125 Iodine-123
  • Molecular imaging
Avid   Radiopharmaceuticals 123I β-amyloid compound
Avid is developing novel radiopharmaceuticals to diagnose and monitor Alzheimer's disease and other pathologies.
Iodine-123
  • Radiolabelling feasibility

CardioGen-82® is a generator-based, cardiac Positron Emission Tomography (PET) perfusion imaging agent. Using a specialized generator technology, it produces Rubidium-82, used to examine blood flow through heart vessels.

Rubidium-82
  • Process development
  • Scale-up
  • Commercial supply
Bradmer   Pharmaceuticals Neuradiab (I-131 anti-
tenascin 81C6 mAb)

Bradmer Pharmaceuticals' novel molecular targeting agent under development for the treatment of Glioblastoma Multiforme (GBM).
Iodine-131
  • Process development
  • Scale-up
  • Clinical trial manufacture
GlaxoSmithKline Bexxar® (Iodine I131Tositumomab)
The Bexxar Therapeutic Regimen is indicated for the treatment of patients with CD 20 antigen expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), including patients with Rituximab-refractory non-Hodgkin's lymphoma.
Iodine-131
  • Process development
  • Scale-up
  • Manufacture
Hologic Iotrex® Radiotherapy Solution (I125 HBS)
Iotrex is a radiotherapy solution to be used in the GliaSite® Radiation Treatment Delivery System, indicated for the treatment of newly diagnosed, metastatic and recurrent brain tumors be delivering radiation from within the cavity created by the surgical removal of the tumor.
Iodine-125
  • Process development
  • Manufacture
Molecular Insight Pharmaceuticals Azedra™ (Ultratrace™ Iobenguane I131)
Under development for the treatment of neuroblastoma and pheochromacytoma.
Iodine-131
  • Process development
Molecular Insight Pharmaceuticals Zemiva™ (Iodofiltic Acid I123)
Zemiva is being developed to detect and manage cardiac ischemia by imaging metabolic changes in the heart.
Iodine-123
  • Process development
  • Scale-up
  • Clinical supply
Morphotek MORAb-003
MORAb-003 is a humanized IgG1 antibody that targets Folate Receptor Alpha which is over-expressed on a number of epithelial-derived cancers such as ovarian, breast, renal, lung, colorectal and brain cancers. MORAb-003 received orphan drug designation by the FDA for ovarian cancer.
Indium-111
  • Radiolabelling
  • Process development
  • Scale-up
  • Clinical supply
Cell   Therapeutics, Inc. Zevalin® (Ibritumomab Tiuxetan)
Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients with Rituximab-refractory follicular NHL.
Yttrium-90
  • Development of Yttrium-90 Chloride Sterile Solution for clinical and commercial distribution


footer